Markers of resistance to anti-EGFR therapy in colorectal cancer |
| |
| Authors: | Walid Shaib Reena Mahajan Bassel El-Rayes |
| |
| Affiliation: | Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA |
| |
| Abstract: | Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC). The benefit from EGFR inhibitors appears to be limited to a subset of patients with CRC. Mechanisms of resistance to EGFR inhibitors are being identified. KRAS codon 12 activating mutation is a predominate mechanism of resistance to EGFR inhibitors in around 40% of patients with advanced CRC. Other potential mechanisms of resistance include ligand expression, increased EGFR number, mutations of BRAF and activation of alternate signaling pathways.Key Words: Resistance, anti-epidermal growth factor receptor (anti-EGFR), colorectal cancer |
| |
| Keywords: | |
|
|
